Type 1 interferons as a potential treatment against COVID-19

Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sallard, Erwan, Lescure, François-Xavier, Yazdanpanah, Yazdan, Mentre, France, Peiffer-Smadja, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138382/
https://www.ncbi.nlm.nih.gov/pubmed/32275914
http://dx.doi.org/10.1016/j.antiviral.2020.104791
_version_ 1783518572643876864
author Sallard, Erwan
Lescure, François-Xavier
Yazdanpanah, Yazdan
Mentre, France
Peiffer-Smadja, Nathan
author_facet Sallard, Erwan
Lescure, François-Xavier
Yazdanpanah, Yazdan
Mentre, France
Peiffer-Smadja, Nathan
author_sort Sallard, Erwan
collection PubMed
description Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.
format Online
Article
Text
id pubmed-7138382
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71383822020-04-08 Type 1 interferons as a potential treatment against COVID-19 Sallard, Erwan Lescure, François-Xavier Yazdanpanah, Yazdan Mentre, France Peiffer-Smadja, Nathan Antiviral Res Article Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19. Elsevier B.V. 2020-06 2020-04-07 /pmc/articles/PMC7138382/ /pubmed/32275914 http://dx.doi.org/10.1016/j.antiviral.2020.104791 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sallard, Erwan
Lescure, François-Xavier
Yazdanpanah, Yazdan
Mentre, France
Peiffer-Smadja, Nathan
Type 1 interferons as a potential treatment against COVID-19
title Type 1 interferons as a potential treatment against COVID-19
title_full Type 1 interferons as a potential treatment against COVID-19
title_fullStr Type 1 interferons as a potential treatment against COVID-19
title_full_unstemmed Type 1 interferons as a potential treatment against COVID-19
title_short Type 1 interferons as a potential treatment against COVID-19
title_sort type 1 interferons as a potential treatment against covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138382/
https://www.ncbi.nlm.nih.gov/pubmed/32275914
http://dx.doi.org/10.1016/j.antiviral.2020.104791
work_keys_str_mv AT sallarderwan type1interferonsasapotentialtreatmentagainstcovid19
AT lescurefrancoisxavier type1interferonsasapotentialtreatmentagainstcovid19
AT yazdanpanahyazdan type1interferonsasapotentialtreatmentagainstcovid19
AT mentrefrance type1interferonsasapotentialtreatmentagainstcovid19
AT peiffersmadjanathan type1interferonsasapotentialtreatmentagainstcovid19

Ejemplares similares